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Abstract
Background: We examined trends in AIDS-defining illnesses (ADIs) among individuals receiving highly active
antiretroviral therapy (HAART) in British Columbia (BC), Canada to determine whether declines in ADIs could be
contributing to previously observed improvements in life-expectancy among HAART patients in BC since 1996.
Methods: HAART-naïve individuals aged ≥ 18 years who initiated treatment in BC each of the following time-
periods 1996 - 1998; 1999 - 2001; 2002 - 2004; 2005 - 2007 were included. The proportion of participants with
reported ADIs were examined for each time period and trends were analyzed using the Cochran-Armitage Trend
Test. Cox proportional hazards models were used to examine factors associated with ADIs.
Results: A total of 3721 individuals (81% male) initiated HAART during the study period. A total of 251 reports of
ADIs were received from 214 unique patients. These occurred in a median of 4 months (IQR = 1-19 months) from
HAART initiation. The proportion of individuals with a reported ADI did not change significantly from 4.6% in the
earliest time period to 5.8% in the latest period (p = 0.181 for test of trend). There were no significant declines in
any specific ADI over the study period. Multivariable Cox models found that individuals initiating HAART during
2002-04 were at an increased risk of ADIs (AHR = 1.55; 95% CI 1.04-2.32) in comparison to 1996 - 98, but there
were no significant differences in other time periods.
Conclusions: Trends in reported ADIs among individuals receiving HAART since 1996 in BC do not appear to
parallel improvements in life-expectancy over the same period.
Background
The introduction of highly active antiretroviral therapy
(HAART) in 1996 resulted in significant reductions in
HIV/AIDS morbidity and improved survival among
HIV-infected individuals compared to the pre-HAART
era [1-6]. These improvements in survival were paral-
leled with reductions in the incidence of AIDS-related
opportunistic infections, in the HAART-era compared
to earlier time periods [7-9]. This trend is further illu-
strated by a continued reduction in the proportion of
death due to ADI’s in HIV infected individuals [10,11].
Life-expectancy of individuals initiating HAART in
British Columbia (BC), Canada has continued to
increase since the introduction of HAART [1]. In 1996-
1998 individuals initiating HAART at the age of 20
years could expect to survive a mean of 11.9 years (stan-
dard deviation [SD] = 2.8 years) [1]. By 2002-2004 this
life-expectancy at age 20 had increased to 23.6 years
(SD = 4.4 years). These findings were confirmed by a
large collaboration of ART treatment cohorts examining
this same issue [6]. Because prior studies have found
that the development of ADIs has resulted in a higher
mortality rate among people living with HIV [12,13] one
might speculate that the continued increase in the survi-
val of HIV patients in the past 15 years is related to a
decrease in the incidence of ADIs. However, to what
extent reduced incidence of ADIs during late- HAART
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eras compared with earlier periods has contributed to
this increase in life-expectancy is unknown.
In this study we examined trends in reported ADIs
among participants who initiated HAART in the BC
HIV/AIDS Drug Treatment Program during the years
1996 to 2007.
Methods
The BC HIV, Drug Treatment Program (DTP) provides
free antiretroviral medications to all medically eligible
HIV-infected individuals free-of-charge [1]. Data for this
study were drawn from the HAART Observational Med-
ical Evaluation and Research (HOMER) cohort. HOMER
is a population-based cohort of antiretroviral-naïve HIV-
infected adults 18 years of age and older who are
enrolled in the DTP. The current HOMER dataset
includes individuals who initiated HAART between
August 1, 1996 and February 28, 2009, with follow-up
until February 28, 2010. However, we restricted inclu-
sion in this analysis to individuals who initiated HAART
before December 31, 2007. Ethical approval for HOMER
has been provided by the University of British Columbia
Research Ethics Board.
CD4 cell counts were measured using flow cytometry
and fluorescent monoclonal antibody analysis (Beckman
Coulter, Inc., Mississauga, Ontario, Canada), and HIV
viral load was measured using the Roche Amplicor
Monitor assay (Roche Diagnostics, Laval, Quebec,
Canada). Adherence to HAART was defined as the
number of days for which HAART is dispensed divided
by the number of days for which HAART is prescribed
in the first year of treatment. Deaths are recorded
through physician reports and through record linkages
between the DTP and the British Columbia Vital Statis-
tic registry. Physicians of DTP participants are mailed a
form to assess the clinical stage of HIV disease each
year, based on the CDC classification, and are mailed
another form if their patient discontinues treatment.
Physician reports of ADIs (CDC Stage C diseases) and
patient characteristics were studied for HOMER partici-
pants who began treatment in each of the following
time-periods: 1996-1998, 1999-2001, 2002-2004, and
2005-2007. We also conducted a data linkage with the
provincial cancer registry in order to identify additional
AIDS-defining cancers which were not reported by phy-
sicians. Patients were followed from the date of starting
HAART until the date of ADI (if a condition was
reported) or the later of date of death or last laboratory
result, to a maximum of 36 months after beginning
therapy. The overall reporting rate by physicians was
calculated by the number of staging and discontinuation
forms returned divided by the number of forms sent.
We compared participant characteristics using Chi-
square and Kruskal-Wallis tests. ADI trends and overall
reporting trends over time were analyzed using the
Cochran-Armitage Trend Test. We calculated 12-
months ADI event rates using life tables and con-
structed Kaplan-Meier curves to examine the time to
first ADI diagnosis. Cox proportional hazards models
were used to examine independent factors associated
with time-to-ADIs. The final multivariate model was
constructed using a backward stepwise procedure, with
era of HAART initiation forced into the model. To
examine the effect of treatment adherence in each era
we ran models with and without adherence measures to
determine if this affected our results. All analyses were
conducted using SAS version 9.1.3 (SAS, Cary, North
Carolina, United States).
Results
A total of 3721 individuals (81% male) initiated HAART
during the study period. The median baseline CD4 count
was 190 cells/μL (interquartile range [IQR] 90 - 310
cells/μL) and 644 (15%) participants had AIDS at base-
line. Table 1 represents the characteristics of participants
in our drug treatment program by era of HAART initia-
tion. There were significant differences in the median
baseline CD4 cell count (p < 0.001), the gender distribu-
tion of participants (< 0.001) and the median age of study
participants (p < 0.001) by time-period of HAART initia-
tion but not in the proportion of individuals with a his-
tory of injection drug use (p = 0.842).
The median follow-up time for all patients was 53
months (IQR 24-101 months) during which there were
251 ADIs reported from 214 patients (Table 2). These
occurred in a median of 4 months (IQR = 1-19 months)
from HAART initiation. Kaposi’s sarcoma (20% of all
ADIs), Pneumocystis jirovecii pneumonia (17%) and
Non-Hodgkin’s lymphoma (15%) were the most com-
monly reported and/or diagnosed ADIs. The proportion
of individuals with at least one reported ADI was 4.5%
for individuals initiating HAART in 1996-98, 5.7% in
1999 - 2001, 7.8% in 2002-04 and 5.5% in 2005-07. We
did not observe a statistically significant trend in the
proportion of participants with any ADI over the study
period (p = 0.130, for test of trend), or any cause-speci-
fic ADI. The median CD4 cell count for those with
ADIs were 140; 95; 70 and 80 cells/μL for each time
period (p = 0.213). The 12-month probability of
reported ADIs in each time-period was as follows: 1996-
98 = 0.020 (95% confidence interval [CI] 0.011-0.029);
1999-2001 = 0.038 (0.025-0.050); 2002-04 = 0.059
(0.042-0.076); 2005-07 = 0.047 (0.034-0.060). A similar
trend was also reflected in the Kaplan-Meier analysis of
ADI-free survival which found significant differences
between the different periods of HAART (log-rank test
p = 0.008), with the 2002 - 2004 period having the high-
est risk of ADI (data not shown).
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In the multivariable model (Table 3), we found that
individuals who initiated HAART in 2002-04 were at
an increased risk for ADIs (adjusted hazard ratio
[AHR] = 1.55; 95% CI 0.81-1.88) in comparison to
1996-98; There were no significant associations with
the time-periods of 1999-2001 (AHR = 1.24 (95% CI
0.81-1.88) or 2005 - 07 (AHR = 1.26 (95% CI 0.85-
1.88) in comparison to 1996-98. Factors which were
associated with risk for ADI included baseline CD4
counts < 50 cells/μL, (AHR = 3.48; 95% CI 2.43-4.99)
and between 50 - 199 cells/μL (AHR = 1.60; 95% CI
1.13-2.26), baseline HIV viral load (AHR = 2.03 per
log10 increase; 95% CI 1.47-2.79); and the inclusion of
NNRTIs in the first drug regimen (AHR = 0.77; 95%
CI 0.56-1.05). A multivariate model which included
adherence to therapy also found no difference in risk
for ADIs associated with the time-period in which par-
ticipants initiated HAART.
We reviewed the number of physician ’s reports
submitted for other programmatic reasons such as
clinical staging or medication discontinuation forms to
see if ADI reports could have been influenced by
changes in overall physician reporting. Our results
indicate that the number of other physician reports
decreased significantly over the study period with 63%
of physicians submitting at least one report in 96-98,
62% in 1999-2001, 44% in 2002-04 and 49% in 2005-
07.(p-value < 0.001).
Discussion
The proportion of individuals with reported ADIs within
36 months of treatment initiation has not changed sig-
nificantly among individuals accessing HAART in BC
over a 12-year period. Considering that the baseline
CD4 remained relatively constant, it was not surprising
that the incidence of reported ADI’s did not significantly
change. However, this result is somewhat unexpected
given the improvements in life-expectancy we have seen
in the same period in this population [1]. Additionally
our observed bias toward decreased overall reporting in
recent years from physicians in our program further
supports our conclusion that ADI rates have not
decreased over this period. Therefore, it appears that
improvement in life expectancy of HIV/AIDS patients in
this period is due to factors other than a decrease in the
incidence of ADIs. Most likely this is due to reductions
in non-AIDS related conditions, but may also be related
to other factors, as well.
The importance of reductions in non-AIDS related
conditions contributing to improvements in clinical out-
comes has been previously highlighted by the SMART
[14,15] study which found that continuous treatment
with HAART decreases the risk of major cardiovascular,
renal and hepatic diseases and mortality rate among
people with HIV.
We did find that individuals who initiated treatment
during 2002-04, did have an increased risk of being
Table 1 Characteristics of participants in the BC HIV/AIDS Drug Treatment Program by era of HAART initiation
ERA (n) 1996-98
(967)
1999-01
(897)
2002-04
(783)
2005-07
(1074)
p-value
N (%) Male 829(85.7) 694(77.4) 630(80.5) 863(80.4) < 0.001
N (%) with history of ever using injection drugs 387(40) 341(38) 305(39) 423(39.4) 0.842
Median age (IQR) 37 (32-43) 38 (33-45) 42 (35-48) 42 (36-49) < 0.001
Median CD4 cell count
(IQR)
280
(120-430)
190
(80-330)
150
(70-230)
180
(100-250)
< 0.001
Table 2 Summary of reported AIDS-defining illnesses (ADI) by year of HAART initiation
ERA (n) 1996-98
(967)
1999-01
(897)
2002-04
(783)
2005-07
(1074)
Total
(3721)
p-value
Any ADI (%) 44
(4.5)
50
(5.6)
61
(7.8)
59
(5.5)
214 (5.75) 0.181
Kaposi’s Sarcoma (%) 7 (0.7) 10 (1.1) 13 (1.7) 12 (1.1) 42 (1.1) 0.295
Pnemocystis jirovecii pneumonia (%) 12 (1.2) 8 (0.9) 7 (0.9) 9 (0.8) 36 (0.97) 0.386
Non-Hodgkin’s Lymphoma (%) 9 (0.9) 9 (1.0) 6 (0.8) 8 (0.7) 32 (0.86) 0.552
Mycobacterium avium intracellae (%) 6 (0.6) 6 (0.7) 11 (1.4) 5 (0.5) 28 (0.75) 0.971
HIV Wasting Snydrome (%) 3 (0.3) 3 (0.3) 6 (0.8) 8 (0.7) 20 (0.54) 0.103
Mycobacterium Tuberculosis (%) 0 (0) 7 (0.8) 4 (0.5) 4 (0.4) 15 (0.40) 0.363
Cryptococcal Meningitis (%) 3 (0.3) 2 (0.2) 5 (0.6) 3 (0.3) 13 (0.35) 0.785
n = number who initiated HAART in each period
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diagnosed with an ADI. However this does not appear
to be part of a trend towards an increased or decreased
risk over time. It is noteworthy that this time-period
was characterized by the lowest median baseline CD4
cell counts (150 cells/μL), but that this relationship per-
sisted even after adjustment for baseline CD4 counts.
Since this period was prior to the release of the SMART
data, when medically supervised treatment interrupted
were considered a reasonable part of clinical manage-
ment, it is possible that such interruptions may have
contributed to the increase incidence of ADIs during
this period.
Our results contrast somewhat with a recent examina-
tion of rates of ADIs among participants in the HIV
Table 3 Cox proportional hazards analysis of time to first AIDS event following initiation of HAART by period of
HAART initiation
Variable Unadjusted Hazard Ratio
(95% CI)
p-
value
Adjusted Hazard Ratio
(95% CI)
p-
value
Adjusted Hazard Ratio
(95% CI)
p-
value
w/adherence w/o adherence
Age (per decade) 1.16 (1.01-1.32) 0.031 1.18 (1.03-1.35) 0.020
Gender 0.133
Female 1.00
Male 1.33 (0.92-1.94)
Baseline AIDS defining illness 1.93 (1.42-2.63) <
0.001
CD4 (per 100 cells) 0.64 (0.57-0.72) <
0.001
Baseline CD4
< 50 4.76 (3.38-6.70) <
0.001
3.56 (2.48-5.11) <
0.001
3.48 (2.43-4.99) <
0.001
50-199 1.93 (1.37-2.70) <
0.001
1.61 (1.14-2.28) 1.60 (1.13-2.26) 0.008
200+ 1.00 1.00 0.007 1.00
Baseline Viral Load (log10) 3.32 (1.99-5.54) <
0.001
2.07 (1.50-2.85) <
0.001
2.03 (1.47-2.79) <
0.001
Baseline Viral Load <
0.001
< 100,000 1.00
> 100,000 2.67 (1.96-3.64)
Third drug of baseline therapy 0.003 0.073 0.096
PI 1.00 1.00 1.00
NNRTI 0.64 (0.47-0.86) 0.75 (0.55-1.03) 0.77 (0.56-1.05)
Hepatitis C 0.595
Negative 1.00 0.560
Positive 1.08 (0.81-1.43)
unknown 1.15 (0.73-1.81)
History of Injection drug use 1.12 (0.85-1.46) 0.424
Year therapy started (per year
increase)
1.03 (0.99-1.07) 0.189
ERA therapy started
96-98 1.00 1.00 1.00
99-01 1.25 (0.83-1.87) 0.286 1.25 (0.82-1.91) 0.293 1.24 (0.81-1.88) 0.320
02-04 1.77 (1.20-2.60) 0.004 1.59 (1.06-2.39) 0.025 1.55 (1.04-2.32) 0.032
05-07 1.26 (0.85-1.86) 0.251 1.36 (0.90-2.04) 0.141 1.26 (0.85-1.88) 0.255
One-year Adherence (per 10%
increase)
0.89 (0.86-0.93) <
0.001
One-year Adherence <
0.001
<
0.001
< 95% 1.00 1.00
≥ 95% 0.50 (0.38-0.65) 0.42 (0.32-0.56)
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Outpatient Study, which did find significant reductions
in the incidence of ADIs between 2003-2007 in compar-
ison to 1998-2002 [16]. The HOPS Study had a larger
number of participants (approximately 9000 in the per-
iod after 1998), but did not restrict their study to indivi-
duals who initiated HAART in each time period,
therefore the two studies are not directly comparable.
Our study was specifically designed to look at the effects
of the changing management and medications associated
with initiating HAART in each time period, rather than
overall ADI incidence rates.
While we did not find significant changes in the rates
of ADIs in later time-periods, a significant minority of
HAART patients continue to experience serious illness
even in the latest time period. Early linkage of HIV
patients to care and better adherence to treatment plan
have been shown to prevent the development of ADIs
[17] and improve clinical outcome [18]. Fortunately, the
median CD4 count at initiation increased in the last
time period and more recent analyses have shown that
this has now climbed to above 200 cells/μL [19]. These
findings highlight the need for better strategies to facili-
tate earlier identification of HIV-infected individuals and
link them to care in BC. Such strategies would likely
result in even further improvements in life-expectancy
for HIV-infected individuals.
There are several limitations to our study. Firstly, the
number of ADIs reported in each time-period was quite
small which limited our ability to detect significant
changes in reported cases. Secondly, we expect that phy-
sicians underreport ADIs events, however, this underre-
porting appears to be greatest in the later time-periods
which should have biased our results towards showing
significant declines, and instead the ADI rate remained
statistically unchanged. Conversely, it is also possible
that physicians have become more astute or vigilant
about reporting AIDS over time. Third, there is a possi-
bility of variations in the quality of reports of cases with
the ADI. This can be less of a problem for ADIs with
clear diagnostic criteria (TB, cryptococcal disease or
cancers) than with more subjective diagnoses (wasting).
Lastly, as with all observational studies the lack of differ-
ence we have observed may be confounded by other fac-
tors which differ between the time-periods and we are
unable to measure.
Conclusions
The overall incidence of ADIs after HAART has not
changed significantly after the introduction of the
HAART in BC. These observations suggest that pre-
viously described recent improvements in the life expec-
tancy among patients initiating HAART might have
been because of reductions in the occurrence of other
non-AIDS related clinical conditions. Further research is
needed to examine this hypothesis.
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